Abstract MicroRNAs (miRNAs) constitute a recently identified class of small endogenous noncoding RNAs that act as negative regulators of the protein-coding gene expression and may impact cell differentiation, proliferation and survival, i.e., all fundamental cellular processes implicated in carcinogenesis. miRNA expression is deregulated in many types of human cancers, including thyroid cancer. The purpose of this review is to summarize the existing findings of miRNA deregulation in thyroid tumors and its potential role in thyroid cancer biology and molecular diagnostics.
Introduction
The central dogma of molecular biology, which describes the relationship between DNA that stores genetic information in the form of individual genes, their transcription into messenger RNA (mRNA), and translation into protein, was recently challenged by the discovery of a new class of regulatory molecules-microRNAs (miRNAs). miRNAs are coded by miRNA genes, which are transcribed into small (∼22 nt) single-stranded RNA molecules that are not further translated into proteins. Instead, they function as negative regulator of coding gene expression and may impact cell differentiation, proliferation, and survival, all fundamental cellular processes implicated in carcinogenesis [1] . miRNAs regulate gene expression by mechanism similar to short interfering RNA (siRNA), i.e., through complementary binding to 3′ untranslated region (UTR) of target mRNA and using RNA interference (RNAi) pathway (Fig. 1) . However, miRNA and siRNA are quite distinct; major differences in their structure and function are depicted in Table 1 . miRNAs genes are estimated to account for 2-5% of human genes [2] . Many miRNA genes are located within introns and exons of proteincoding genes and in the intergenic regions. Frequently, miRNAs are located in clusters and transcribed as polycistrons and, therefore, have similar expression patterns [2, 3] . For example, miR-221 and miR-222 are in one cluster located on chromosome X, and this explains their concordant expression patterns in several human carcinomas, including thyroid carcinomas [3] .
Production and function of miRNAs involves multiple steps and requires a large set of proteins [2] (Fig. 2) . First, a miRNA gene is transcribed by RNA polymerases II into a long hairpin structure known as primary miRNA (primiRNA) [4, 5] . The latter is processed by RNAse III enzyme Drosha and its RNA binding partner DGCR8 into an about 70-nucleotide-long precursor miRNA (premiRNA) [6] before nuclear export by Exportin-5 [7, 8] . In the cytoplasm, pre-miRNA undergoes further processing by the endonuclease enzyme Dicer into mature miRNA. Mature miRNA is incorporated into RNA-induced silencing complex (RISC), an enzyme complex guiding the endonucleolytic activity of RNAi pathway [9] , and binds to the 3′ untranslated region of mRNA. If the miRNA has perfect complementarity to the 3′ UTR region of the target mRNA, it induces the mRNA cleavage. If the miRNA and mRNA do not match perfectly, it results in translational repression and inhibition of protein synthesis (Fig. 2) . The nonperfect complementarity allows a single miRNA to target multiple genes. It was approximated that one miRNA can potentially regulate more than 200 different genes. On the other hand, many individual genes have in their 3′ UTR predicted target sites for multiple miRNAs, indicating the likelihood of a combinatory action of several miRNAs on gene activity.
miRNA deregulation is common in cancer cells, and a rapidly growing pool of studies provides evidence for miRNA involvement in carcinogenesis. Specific subsets of overexpressed and downregulated miRNAs have been identified in various tumor types, suggesting that aberration in miRNA expression is important in tumor development and progression. Overexpression of a miRNAs could result in downregulation of tumor suppressor genes (oncogenic miRNAs or oncomiRs), and underexpression of miRNAs could lead to upregulation of oncogenes (suppressor miRNAs) with subsequent effects on cell proliferation, apoptosis, angioinvasion, and other carcinogenic actions (Fig. 3) . The list of miRNAs with known cancer gene targets is rapidly growing [10] . For example, let-7 negatively regulates Ras [11] , miR-221 and miR-222 downregulate KIT receptor [12] and CDKN1B (p27/Kip1) protein, a key player in cell cycle control [13] , and miR-16-1 and miR-15a downregulate BCL2 [14] . Unique signatures of miRNA expression are described in a variety of epithelial and lymphoid malignancies [15] .
The mechanisms of miRNA deregulation in neoplastic cells are not well understood. miRNA genes appeared to be commonly mapped to minimal regions of amplification, loss of heterozygosity, and breakpoint regions implicating genomic abnormalities as a cause of miRNA deregulation [16] . Some data support the existence of epigenetic regulation of miRNA expression, such as by DNA hypomethylation or hypermethylation of CpG islands in the miRNA promoter regions and by histone modification [17, 18] . Transcriptional factors may also be involved and induce miRNA expression by activating the transcription of miRNA precursor (pri-miRNA) [19, 20] . Deregulation of the miRNA processing steps is documented in several human cancers [21, 22] and may lead to changes in miRNA expression in a given neoplastic cell.
miRNA Deregulation in Thyroid Cancer
Most thyroid carcinomas originate from thyroid follicular cells. The two most common cancer types are welldifferentiated papillary carcinoma (PC) and follicular carcinoma (FC); the latter is further subclassified into conventional and oncocytic types. Both PCs and FCs may progress to poorly differentiated carcinoma (PDC) or may completely loose differentiation and transform to anaplastic carcinoma (AC). Follicular adenoma (FA) is a benign thyroid tumor and can be of either conventional or oncocytic types. Medullary carcinoma (MC) originates from the thyroid C cells and accounts for less than 5% of thyroid tumors.
Our current understanding of miRNA deregulation in thyroid carcinomas is based on several independent studies that collectively analyzed more than 200 thyroid tumors [23] [24] [25] [26] [27] [28] [29] . Snap-frozen tissue was the most commonly used miRNA source; however, the utility of formalin-fixed paraffin-embedded (FFPE) tissue for miRNA analysis was validated in a variety of human tissues [30] including thyroid [26, 27, 29] .
Analysis of miRNA expression in normal thyroid tissue and in major types of thyroid tumors revealed that majority of known miRNAs were expressed in normal thyroid tissues, whereas in thyroid neoplasms 32% of miRNAs were found to be consistently upregulated, and 38% were downregulated with more than a 2-fold change as compared to normal tissue [24] . There was no global downregulation of miRNA expression in less differentiated carcinomas (PDCs and ACs) as compared to well-differentiated thyroid carcinomas (PCs, FCs, and MCs) in contrast to the reported study that found overall decrease in miRNA expression in poorly differentiated tumors as compared with their welldifferentiated counterparts in several types of cancer [31] . From the early stages of miRNA discovery, it has been known that miRNA expression profiles are tissue specific. A study of all major types of thyroid neoplasia showed that miRNA expression profile of C-cell-derived MCs is significantly different from the miRNA profiles of thyroid tumors that originate from follicular cells [24] . Moreover, even among tumors originating from the same cell type, miRNA expression profiles had significant variability. Papillary carcinomas, conventional follicular tumors (adenomas and carcinomas), and oncocytic follicular tumors (adenomas and carcinomas) revealed separate clusters. Less 
miRNA Expression in Papillary Thyroid Carcinomas
Most studies have focused on miRNA analysis of PC (Table 2) [23] [24] [25] [26] 29] . As evident from the table, most of the studies have identified several miRNAs (miR-146b, miR-221, miR-222, miR-181b, miR-155, and miR-224) upregulated in PCs. Of interest, many of these miRNAs were upregulated as compared to normal thyroid cells and hyperplastic nodules; however, one miRNA (miR-181b) was found to be upregulated in both thyroid tumors and hyperplastic nodules [24] .
Correlation of miRNA Expression with Somatic Mutations
Genetically, PCs feature mutually exclusive (non-overlapping) mutations in the RET, RAS, and BRAF genes [32] , all capable to activate the mitogen-activated protein kinase signaling pathway [33] . These mutations are associated with distinct gene expression profiles and distinct phenotypic features of PC [34] . BRAF mutation is linked to higher risk of PC recurrence and increased mortality [35, 36] .
A study of miRNA expression in PCs with known mutations revealed a strong correlation between the miRNA profile and mutational status. Papillary carcinomas positive for BRAF, RET/PTC, and RAS mutations, and those with no known mutations demonstrated significant differences in the expression of certain miRNAs [24] . For example, miR-187 was expressed at higher levels in PCs harboring RET/ PTC rearrangements; miR-221 and miR-222 were found at the highest levels in BRAF-and RAS-positive tumors and tumors with no known mutations and the highest expression of miR-146b in PCs carrying RAS mutations [24] . Principal component analysis, used for unsupervised assessment of the relationship between miRNA expression and mutation type, revealed formation of individual clusters for BRAF-and RET/PTC-positive tumors and tumors with no known mutations [24] (Fig. 4) . Only RAS-positive tumors did not show clear separation from other clusters. In addition, some differences in expression of individual miRNAs was found in thyroid cell lines carrying BRAF and RET/PTC mutations as compared to normal thyroid cell lines [37, 38] . However, none of the differently expressed miRNAs were noted in studies of human thyroid tumors [23] [24] [25] [26] 29] providing evidence for significant differences in miRNA status between thyroid cells in vivo and in vitro.
miR-221 and miR-222 as Potential Regulators of the KIT and CDKN1B(p27Kip1) Genes
MiR-222 and miR-221 are most consistently upregulated in PC. One of the genes that appear to be targeted by these miRNAs is KIT [12] . KIT is a tyrosine kinase receptor involved in cell differentiation and growth. Reduced KIT levels in PCs were reported more than a decade ago, but the mechanism of downregulation was not clear [39] . More recently, He et al. showed that downregulation of KIT protein correlates with strong overexpression of miR-221, -222, and miR-146b [23] . Sequencing of miR-221 and -222 binding domains of KIT 3′ UTR revealed a G3169A single nucleotide polymorphism within the miR-221 and miR-222 recognition sites in several PCs. The G3169A variation is expected to modify the miRNA binding to the KIT mRNA and decrease the efficiency of the miRNA-mediated translational inhibition of KIT. Another direct consequence of the mir-221 and miR-222 upregulation in PCs is reduction in the levels of CDKN1B (p27Kip1) protein and increased progression to the S phase of cell cycle [13] . Of [29] note, the inverse relationship between the expression of Kip/Cip family members p27 and p57 and miR-221 and miR-222 was also observed in prostate carcinoma and glioblastoma cell lines [40, 41] .
miRNA Expression in Other Thyroid Tumors
Although most observation reported so far have focused on miRNA expression in papillary thyroid carcinomas, we also start to gain insights into miRNA deregulation in follicular thyroid carcinomas and adenomas [24, 28] , anaplastic and poorly differentiated thyroid carcinomas [24, 27] , and medullary carcinoma [24] ( Table 3 ). The most highly upregulated miRNAs in conventional FCs were miR-187, -224, -155, -222, and -221 and in OCs were miR-187, -221, -339, -183, -222, and -197 [24] . Interestingly, those miRNAs were not significantly upregulated in hyperplastic nodules. In a study by Weber et al., miR-197 and miR-346 were found to be upregulated in FCs as compared to FAs [28] . Moreover, in the in vitro experiments, the overexpression of these miRNAs induced cell proliferation of human nonneoplastic HEK293T cells, whereas the inhibition of miR-197 and miR-346 led to growth arrest in FTC133 human thyroid cancer follicular cells, providing further evidence for their possible role in FC carcinogenesis [28] . miRNA analysis of ACs revealed upregulation of the several miRNAs that were also found to be overexpressed in well-differentiated tumors deriving from follicular cells, although the levels of overexpression were lower in ACs [24] . In addition, miR-302c, -205, and -137 were found to be upregulated more than 2-folds in ACs as compared to hyperplastic nodules. Many miRNAs were downregulated in ACs; in particular, a significant decrease in expression of miR-30d, miR-125b, miR-26a, and miR-30a-5p was detected [27] . In vitro, the overexpression of miR-125b and miR-26a was able to reduce cell growth and proliferation of two human AC-derived cell lines, suggesting a possible role of these miRNAs in thyroid cancer progression and dedifferentation [27] Diagnostic Implications of miRNA Profiling in Thyroid Tumors Palpable thyroid nodules are common and affect 4-7% of adults in the USA [42] . Although fine-needle aspiration (FNA) of thyroid nodules is a safe and accurate tool in the diagnosis of thyroid cancer, about 15% of cases are reported as indeterminate. Most of these nodules will be surgically removed, and only 8-17% of them will be malignant [42] . Further improvement of diagnostic precision is achieved by supplementary testing of FNA material for somatic mutations known to occur in thyroid tumors [43, 44] . However, the sensitivity of such testing is limited because a significant proportion of PCs and FCs (25-30%) do not harbor any known mutations. These cases would benefit most from additional diagnostic modalities, such as miRNA profiling. The major challenge in the preoperative FNA diagnosis is to differentiate between the follicularpatterned thyroid cancers and hyperplastic nodules, which are common in general population. Therefore, a diagnostically useful assay has to distinguish thyroid cancer not only from normal thyroid tissue but also from hyperplastic nodules. A recent study explored the diagnostic benefits of miRNA detection in freshly collected FNA samples obtained for pre-operative evaluation of thyroid nodules [24] . Based on the level of miRNA upregulation in the surgical samples of PCs, FCs and other types of thyroid carcinomas as compared to hyperplastic nodules, a set of seven miRNAs (miR-187, miR-221, miR-222, miR-146b, miR-224, miR-155, miR-197) was selected. Many of these miRNAs were upregulated in the FNA samples obtained from the nodules found to be malignant after surgery but not in benign hyperplastic nodules and nodules with negative cytology and no clinical evidence of thyroid disease. When three or more miRNAs in the panel were upregulated >2-fold, the sensitivity of cancer detection was 88%, specificity 100%, with 98% accuracy [24] . In addition, analysis of these miRNAs allows detection of thyroid malignancy independent of the mutational status. In a different study, miR-221, -222, and -181b expression was evaluated in eight fixed thyroid FNA samples obtained from patients diagnosed with PC after surgery [25] . Upregulation of these miRNAs was detected in seven out of eight FNA samples as compared to normal thyroid cells. These studies demonstrate feasibility of miRNA testing in thyroid surgical and FNA samples and provide evidence for potential usefulness of miRNA profiling. The available data provide a basis for larger prospective trials addressing the utility of miRNA analysis as a diagnostic aid in preoperative evaluation of thyroid nodules.
